Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma

被引:10
|
作者
Lin, Haoming [1 ]
Zhang, Rui [1 ]
Wu, Wenrui [1 ]
Lei, Liming [2 ]
机构
[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pancretobiliary Surg, Guangzhou 510120, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Cardiovasc Inst, Dept Intens Care,Unit Cardiovasc Surg,Lab South C, Guangzhou 510080, Guangdong, Peoples R China
关键词
Hepatocellular carcinoma; Sorafenib resistance; Transcription factors; Dysfunctional gene; Molecular mechanisms; DRUG-RESISTANCE; MESENCHYMAL TRANSITION; DOWN-REGULATION; UP-REGULATION; CANCER-CELLS; EXPRESSION; EFFICACY; SENSITIZES; IMMUNITY; PATHWAY;
D O I
10.1016/j.cancergen.2020.04.076
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Hepatocellular carcinoma (HCC) is an intractable disease because patients with HCC frequently develop sorafenib resistance after long-term chemotherapy. Although studies has demonstrated the availability of cumulative information on drug-resistant patients, little is known about the strategies and molecular mechanisms to reverse sorafenib resistance. Here, the present study identified critical mRNAs and transcription factors (TFs) associated with sorafenib resistance of HCC and evaluated the significance correlation between drug-resistant genes and TFs in comprehensive network for HCC xenografts mice. Methods: The expression profiles of mRNAs were compared between sorafenib-acquired resistant tissue and sorafenib sensitive tissue utilizing RNA-Seq data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Gene Ontology and KEGG pathway analysis were performed to investigate the biological function of significantly dysregulated mRNA. Furthermore, the Kaplan-Meier survival analyses were performed to evaluate the effect of mRNA on over survival. Subsequently, TFs were predicted using TRANSFAC and TF-mRNA regulatory networks were visualized using cytoscape software. Results: A total of 827 mRNAs were found to be differentially expressed in sorafenib-acquired resistant tissue compared with control. Thereafter, the results of functional enrichment analysis showed the dysregulated mRNAs involved in drug-resistant signaling pathway, including MAPK, JAK-STAT, TGF-beta and drug-metabolism cytochrome P450 signaling pathway. CDK1, CDKN1A and TAPBP might serve as prognostic signature of resistance of HCC to sorafenib according to the survival analysis. Furthermore, TF-mRNA networks were constructed. There were 18 TFs were predicted to regulate differentially expressed mRNAs, which play an essential role in the regulation of dysfunctional gene networks. NFKB1 was presented in the TF-mRNA networks as the node with the highest degree and MYC was predicted as prognostic TF in drug resistance of HCC Conclusions: Taken together, our findings showed that novel mRNAs and TFs, which served as critical biomarkers to predict survival and therapeutic targets of resistance to sorafenib in HCC. Furthermore, we constructed the TF-mRNA networks, which provides valuable theoretical references to further evaluate the molecular mechanisms of resistance to sorafenib in HCC. (C) 2020 Published by Elsevier Inc.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 50 条
  • [41] Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma
    Liu, Jing
    Qiu, Wancheng
    Shen, Xiaoying
    Sun, Guangchun
    MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2019, 16 (06) : 6319 - 6334
  • [42] Mechanisms of doxorubicin resistance in hepatocellular carcinoma
    Cox, Josiah
    Weinman, Steven
    HEPATIC ONCOLOGY, 2016, 3 (01)
  • [43] Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma
    Manfredi, Giulia Francesca
    Celsa, Ciro
    John, Chloe
    Jones, Charlotte
    Acuti, Nicole
    Scheiner, Bernhard
    Fulgenzi, Claudia Angela Maria
    Korolewicz, James
    Pinter, Matthias
    Gennari, Alessandra
    Mauri, Francesco A.
    Pirisi, Mario
    Minisini, Rosalba
    Vincenzi, Federica
    Burlone, Michela
    Rigamonti, Cristina
    Donadon, Matteo
    Cabibbo, Giuseppe
    D'Alessio, Antonio
    Pinato, David James
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 1955 - 1971
  • [44] Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma
    Wei, Shuhua
    Wei, Fenghua
    Li, Mengyuan
    Yang, Yuhan
    Zhang, Jingwen
    Li, Chunxiao
    Wang, Junjie
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 163
  • [45] Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma
    Xiao, Hong
    Chen, Hangyu
    Zhang, Lei
    Duolikun, Maimaitiyasen
    Zhen, Baixin
    Kuerban, Subinuer
    Li, Xuehui
    Wang, Yuxi
    Chen, Long
    Lin, Jian
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [46] MiRNA Expression Profiling of Sorafenib Response and Resistance in Hepatocellular Carcinoma
    Yousef, George
    Butz, Henriett
    Kerbel, Robert
    Mozes, Roy
    Patocs, Attila
    Kerbel, Robert
    LABORATORY INVESTIGATION, 2015, 95 : 200A - 201A
  • [47] Galectin-1 modulates sorafenib resistance in hepatocellular carcinoma
    Tung, Hsu W.
    Su, Yen H.
    Chiu, Ching F.
    Chen, Hsin A.
    Shen, Shing C.
    CANCER SCIENCE, 2022, 113 : 1058 - 1058
  • [48] Regorafenib but not sorafenib suppresses ERK signaling in human hepatocellular carcinoma acquiring sorafenib resistance
    Hashiba, Tomomi
    Yamashita, Taro
    Okada, Hikari
    Hayashi, Takehiro
    Yoshida, Mariko
    Sunagozaka, Hajime
    Honda, Masao
    Kaneko, Shuichi
    HEPATOLOGY, 2016, 64 : 248A - 248A
  • [49] Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
    Zeng, Zhi
    Lu, Qiliang
    Liu, Yang
    Zhao, Junjun
    Zhang, Qian
    Hu, Linjun
    Shi, Zhan
    Tu, Yifeng
    Xiao, Zunqiang
    Xu, Qiuran
    Huang, Dongsheng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [50] Unraveling metabolic vulnerabilities to counteract sorafenib resistance in hepatocellular carcinoma
    Pedretti, S.
    Palermo, F.
    Tomaiuolo, P.
    Imperato, G.
    Braghin, M.
    Celikag, M.
    Crestani, M.
    De Fabiani, E.
    Mitro, N.
    FEBS OPEN BIO, 2024, 14 : 29 - 29